Picard Medical / SynCardia to Host Annual Business Update Featuring Key Opinion Leaders and Patient Testimonial

Rhea-AI Summary

Picard Medical (NYSE American: PMI) will host its Annual Business Update webcast on March 25, 2026 at 4:30 p.m. EDT following the filing of its Form 10-K for the fiscal year ended December 31, 2025.

The webcast will review fiscal 2025 and Q4 results, cover commercial activity, operational progress, the next‑generation fully implantable Emperor platform, feature clinician perspectives, and include a patient testimonial.

News Market Reaction – PMI

-4.65%

11 alerts

-4.65% Session close to close

+12.3% Peak in 4 hr 27 min

$99.50M Market Cap

0.2x Rel. Volume

In the Mar 13 session, PMI declined 4.65%, reflecting a moderate negative market reaction. Argus tracked a peak move of +12.3% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement schedules an Annual Business Update after the Form 10-K for the year ended Decembe...

Analysis

This announcement schedules an Annual Business Update after the Form 10-K for the year ended December 31, 2025, combining a financial review with discussion of SynCardia’s commercial activities and the Emperor fully implantable total artificial heart platform. Historical news flow has focused on clinical training and data. Investors may monitor disclosed 2025 results, any updates on Emperor development, and how management frames capital needs following recent proxy and registration statements.

Key Figures

Business update date: March 25, 2026 Webcast time: 4:30 p.m. EDT Fiscal year-end: December 31, 2025

3 metrics

Business update date March 25, 2026 Scheduled Annual Business Update webcast

Webcast time 4:30 p.m. EDT Start time for Annual Business Update

Fiscal year-end December 31, 2025 Form 10-K reporting period

Historical Context

5 past events · Latest: Mar 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 02	Conference data update	Positive	+0.0%	New SynCardia and Emperor data presented at THT 2026 conference.
Feb 26	Training day participation	Positive	-0.9%	Announcement of hands-on SynCardia training at THT 2026.
Feb 23	Surgical training event	Positive	-7.1%	Invitation-only surgical training program at Houston Methodist.
Feb 12	Clinical case milestone	Positive	-1.2%	Successful bridge-to-transplant case using SynCardia Total Artificial Heart.
Feb 10	Conference presentation	Positive	-4.2%	Planned Emperor Total Artificial Heart presentation at European summit.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent clinically focused and conference-related news has generally been positive in tone but often met with flat or negative next-day price reactions.

Recent Company History

Over the last month, PMI has highlighted clinical training, conference participation, and SynCardia Total Artificial Heart milestones. Events on Feb 10, Feb 12, Feb 23, and Feb 26 all carried constructive clinical or commercial messages yet saw next-day moves between -0.86% and -7.14%. A THT 2026 data showcase on Mar 2 produced a flat reaction. Today’s business update announcement fits this pattern of positive operational news against muted to negative trading.

Key Terms

total artificial heart, form 10-k, u.s. fda, cardiothoracic surgeon, +1 more

5 terms

total artificial heart medical

"maker of the world’s first total artificial heart approved by both the U.S. FDA"

A total artificial heart is a surgically implanted mechanical device that replaces the heart’s two main pumping chambers and takes over circulation, acting like a continuous pump that keeps blood moving through the body. Investors care because it is a high-cost, high-stakes medical product whose commercial success depends on clinical trial results, regulatory approvals, hospital adoption, reimbursement rules and long-term patient outcomes — factors that drive revenue potential and risk.

form 10-k regulatory

"following the filing of the Company’s Form 10-K for the fiscal year"

A Form 10-K is a comprehensive report that publicly traded companies are required to file annually with regulators. It provides a detailed overview of a company's financial health, operations, and risks, similar to a detailed health report. Investors use this information to assess the company's performance and make informed decisions about buying or selling its stock.

u.s. fda regulatory

"total artificial heart approved by both the U.S. FDA and Health Canada"

The U.S. FDA is the federal agency that reviews and approves drugs, vaccines, medical devices and food products for safety and effectiveness before they can be sold in the United States. For investors, FDA actions act like a gatekeeper — approvals can open the door to large sales and higher company value, while rejections, delays or safety warnings can sharply cut a product’s market potential and a company’s revenue outlook.

cardiothoracic surgeon medical

"Dr. Zain Khalpey, cardiothoracic surgeon and Surgical Director of the Artificial Heart"

A cardiothoracic surgeon is a medical specialist who performs operations on the heart, lungs and other organs inside the chest; think of them as a highly trained mechanic for the body’s core systems. Investors watch outcomes, procedure volumes and adoption of new devices or techniques by these surgeons because their work drives hospital revenue, validates medical technologies, and influences reimbursement and regulatory risk tied to healthcare and medical-device businesses.

mechanical circulatory support medical

"Surgical Director of Heart Transplantation and Mechanical Circulatory Support at the University"

Mechanical circulatory support are medical devices that help or take over the heart’s job of moving blood around the body, ranging from temporary external pumps to implanted pumps that assist one or both sides of the heart. For investors, these devices matter because their use drives sales, regulatory scrutiny, reimbursement decisions and long‑term healthcare costs; think of them as a backup engine for a failing heart whose adoption and outcomes influence a company’s market opportunity and risk profile.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TUCSON, Ariz., March 12, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will host an its Annual Business Update virtual call, which will be webcasted, on Wednesday, March 25, 2026 at 4:30 p.m. EDT, following the filing of the Company’s Form 10-K for the fiscal year ended December 31, 2025. The webcast will feature business updates from management, including discussion of the Company’s commercial activities and development of its next-generation, fully implantable total artificial heart platform known as Emperor, as well as perspectives from leading clinicians in the cardiac surgical field and a patient who received the SynCardia Total Artificial Heart (STAH). To register for the event, please click here.

On the webcast, management will provide a review of Picard Medical’s fiscal year and fourth quarter 2025 financial results, along with a business update from management covering operational progress, commercial activity, and strategic priorities. Presentations will be delivered by Patrick NJ Schnegelsberg, Chief Executive Officer; Matthew Schuster, Chief Operating Officer; and Bernard Skaggs, Chief Financial Officer.

The program will include perspectives on implantation of the SynCardia Total Artificial Heart and the evolving artificial heart landscape from leading clinicians, Dr. Zain Khalpey, cardiothoracic surgeon and Surgical Director of the Artificial Heart Program at HonorHealth in Phoenix, and Dr. Amy Fiedler, Associate Professor of Surgery and Surgical Director of Heart Transplantation and Mechanical Circulatory Support at the University of California San Francisco. The event will also feature a patient testimonial reflecting clinical experience with the device.

About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the circulatory functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.

For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.

Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, http://www.sec.gov.

Contact:

Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com

Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com

General/Media
Brittany Lanza
blanza@syncardia.com

FAQ

When is the Picard Medical (PMI) Annual Business Update webcast scheduled and how can I join?

The webcast is scheduled for March 25, 2026 at 4:30 p.m. EDT. According to the company, registration is required via the investor webcast link. The program will be available as a live webcast and will follow the filing of Picard Medical's Form 10-K for fiscal 2025.

What will Picard Medical (PMI) cover in its March 25, 2026 business update?

Picard will review fiscal year 2025 and fourth-quarter results and discuss commercial and operational progress. According to the company, management will also cover strategic priorities and development of the Emperor fully implantable total artificial heart platform.

Which Picard Medical (PMI) executives will present during the Annual Business Update webcast?

Presenters include CEO Patrick NJ Schnegelsberg, COO Matthew Schuster, and CFO Bernard Skaggs. According to the company, each executive will deliver updates on financial results, operations, and commercial activities during the webcast.

Will clinicians and patients speak at the Picard Medical (PMI) March 25, 2026 event?

Yes. The webcast includes perspectives from clinicians and a patient testimonial. According to the company, Dr. Zain Khalpey and Dr. Amy Fiedler will discuss implantation and the artificial heart landscape, plus a patient will share their clinical experience with the SynCardia Total Artificial Heart.

Will the Picard Medical (PMI) webcast discuss the Emperor next‑generation platform?

Yes. The company will discuss development of the Emperor fully implantable total artificial heart platform. According to the company, management will provide updates on Emperor alongside commercial activity and operational progress during the March 25 webcast.